

Cytokine profiles in children with primary Epstein-Barr virus infection

著者	Wada Taizo, Muraoka Masahiro, Yokoyama Tadafumi, Toma Tomoko, Kanegane Hirokazu, Yachie Akihiro
journal or publication title	Pediatric Blood and Cancer
volume	60
number	7
page range	E46-E48
year	2013-07-01
URL	http://hdl.handle.net/2297/35105

doi: 10.1002/pbc.24480

Cytokine Profiles in Children with Primary Epstein-Barr Virus Infection

Taizo Wada,¹ Masahiro Muraoka,¹ Tadafumi Yokoyama,¹ Tomoko Toma,¹ Hirokazu Kanegane,² and Akihiro Yachie¹

¹Department of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan; ²Department of Pediatrics, Graduate School of Medicine and Pharmaceutical Science, University of Toyama, Toyama, Japan.

Correspondence to: Taizo Wada, MD, PhD
Department of Pediatrics, School of Medicine,
Institute of Medical, Pharmaceutical and Health Sciences,
Kanazawa University
13-1 Takaramachi, Kanazawa 920-8641, Japan
Phone: +81-76-265-2313
Fax: +81-76-262-1866
E-mail: taizo@staff.kanazawa-u.ac.jp

Running title: Cytokine profiles in primary EBV infection

Keywords: Epstein-Barr virus, hemophagocytic lymphohistiocytosis, infectious mononucleosis, cytokine

Abstract

Primary Epstein-Barr virus (EBV) infection causes infectious mononucleosis and hemophagocytic lymphohistiocytosis (HLH) in children, where EBV infects B and CD8⁺ T cells, respectively. We measured pro-inflammatory and anti-inflammatory cytokines in both diseases. Significantly higher concentrations of various mediators, including interferon- γ , neopterin, interleukin (IL)-6, IL-10, IL-18 and heme oxygenase-1, were observed in EBV-HLH. Because of their similarity to the profile of familial HLH, this profile was likely a consequence of HLH, but not ectopic infection. TNF- α levels were elevated in both diseases. Elevation of those mediators may contribute to the disease pathogenesis of EBV-HLH by activating and inhibiting host immune responses.

Introduction

Epstein-Barr virus (EBV) is a ubiquitous virus that infects the majority of the world's population [1]. Primary infection of EBV is usually asymptomatic but may cause infectious mononucleosis (IM). EBV infects B cells in EBV-associated IM (EBV-IM) and persists in B cells for the lifetime of the seropositive normal host. However, primary EBV infection has also been linked with hemophagocytic lymphohistiocytosis (HLH), which is an aggressive lymphoproliferative disorder [2,3]. Several reports have demonstrated that EBV infection is characterized by an increase in CD8⁺T cells in EBV-HLH, although the mechanism underlying ectopic EBV infection remains unclear [4-7].

The symptoms of EBV-IM and EBV-HLH are associated with T-cell activation and cytokine production [8]. In EBV-IM, proliferation of activated antigen-specific and nonspecific cytotoxic CD8⁺T cells leads to release of interferon (IFN)- γ , interleukin (IL)-2, and tumor necrosis factor (TNF)- α [9,10]. Studies of cytokines from HLH patients have also demonstrated elevated concentration of many pro-inflammatory cytokines, such as IFN- γ , TNF- α , and IL-6 [11-13]. However, because HLH is a heterogeneous group of disorders, most reports have contained subgroups with different disease etiologies [11-13]. Moreover, the cellular targets and clonality of EBV have not been well characterized, even in reports describing EBV-HLH [11-13]. It is therefore unknown whether the differential cellular targets of EBV lead to different cytokine profiles. In this report, we analyzed markers considered to be key in patients with EBV-IM and EBV-HLH.

Methods

Study population

We studied 22 patients with primary EBV infection: 11 with EBV-HLH and 11 with EBV-IM (Table I). All patients were previously healthy. The data of 6 patients with EBV-HLH have been reported elsewhere [5]. The remaining patients with EBV-HLH also showed typical clinical features of HLH and exhibited high viral copy numbers. It was noted that CD8⁺ T cells were the major cellular targets of EBV in all EBV-HLH patients by *in situ* hybridization for EBV-encoded small RNA1 in the available samples [5]. The diagnosis of EBV-IM was clinically determined. All patients with EBV-IM exhibited self-limited disease. Primary EBV infection was serologically confirmed for all cases of EBV-HLH and EBV-IM. We also investigated 4 cases of familial HLH (FHL) due to perforin deficiency as a disease control. Samples were collected during the acute phase of the diseases. The study was approved by the Human Research Committee of Kanazawa University Graduate School of Medical Science, and informed consent was obtained according to the Declaration of Helsinki.

Cytokine determination

Serum or plasma concentrations of cytokines were determined using the following ELISA kits: neopterin (IBL, Hamburg, Germany); IFN- γ , IL-6, TNF- α , soluble TNF receptor type 1 (sTNF-RI) and type 2 (sTNF-RII), and soluble CD163 (sCD163) (R&D systems, Minneapolis, MN); IL-18 (MBL, Nagoya, Japan); IL-10 (eBioscience, San Diego, CA); and heme oxygenase-1 (HO-1; Enzo, Ann Arbor, MI) [14,15]. Analysis of

significant differences among groups was performed using the Mann-Whitney *U* test. Differences with *p*-values less than 0.05 were considered significant.

Results

Patients with EBV-HLH exhibited high levels of IFN- γ , neopterin, IL-6, IL-18, TNF- α , sTNF-RI and sTNF-RII (Figure 1), all of which were statistically significant. Patients with EBV-IM also showed high concentrations of pro-inflammatory cytokines, albeit at lower levels than those of EBV-HLH. Six of 11 patients with EBV-IM showed high TNF- α levels similar to those of EBV-HLH, which was consistent with a previous report [9]. IL-10 was markedly elevated in patients with EBV-HLH, whereas patients with EBV-IM exhibited only modestly elevated IL-10 levels. The levels of sCD163 were elevated in both EBV-HLH and EBV-IM. Patients with EBV-HLH exhibited higher levels of HO-1 compared with those of EBV-IM.

Discussion

In this report, we describe cytokine profiles from children affected with EBV-HLH and EBV-IM. While both diseases are characterized by acute systemic inflammatory responses induced by primary EBV infection, the clinical courses are quite different. EBV-HLH is a potentially fatal disease that often requires immune-modulating

chemotherapy, whereas EBV-IM is a benign self-limited disease. This difference may be fundamentally due to the differential cellular targets of EBV infection; EBV ectopically infects CD8⁺ T cells in EBV-HLH, while B cells are the target in EBV-IM [4-6].

Alternatively, the patients may develop HLH based on the ability of the immune system to cope with this pathogen. However, it remains unknown whether the differential cellular targets of EBV lead to different cytokine profiles in the peripheral blood. To address this issue, serum or plasma concentrations of various cytokines were determined.

Hypersecretion of pro-inflammatory cytokines produced by activated T cells and macrophages accounts for the severe systemic manifestations in HLH [2,3]. In fact, our patients with EBV-HLH exhibited profound hypercytokinemia. The high concentration of neopterin might indicate pathological activation of macrophages and involvement in the disease development of EBV-HLH [16]. These cytokine profiles were similar to those found in FHL caused by perforin deficiency, which is the most common form of genetic HLH [2,3]. The cytokine profile of EBV-HLH is therefore likely a general consequence of HLH, rather than a result of clonal proliferation of EBV-infected CD8⁺ T cells. Some patients with EBV-IM exhibited marked immune responses to regulate EBV-infected B cells and shared typical findings of HLH, such as cytopenia and hemophagocytosis. Because such patients tended to exhibit higher levels of pro-inflammatory cytokines, it was difficult to clearly distinguish EBV-HLH from EBV-IM based solely upon the cytokine profiles. However, we have used flow cytometry to detect EBV-infected cells in EBV-HLH as clonally-expanded and highly-activated CD8⁺ T cells with CD5 downregulation [5,6]. Since suppression of severe hyperinflammation and eradication of EBV-infected cells are crucial in treatment of EBV-HLH [17], the combined analysis of

cytokine profiles and our flow cytometry approach may be useful in follow-up of patients with EBV-HLH.

To evaluate the anti-inflammatory responses in EBV-HLH and EBV-IM, we also analyzed circulating mediators, including IL-10, sCD163 and HO-1 (Figure 1). IL-10 plays multiple roles in immunosuppression and contributes to maintaining the balance of the immune system in inflammation. Consistent with previous reports [11-13], IL-10 was markedly elevated in EBV-HLH patients. EBV-infected cells in EBV-HLH secrete viral IL-10, a product of the EBV replication gene *BCRF1*, which shares structural and functional similarity with human IL-10 [18]. However, patients with FHL exhibited levels of IL-10 that were comparable to EBV-HLH, suggesting that the high IL-10 levels in EBV-HLH were likely a consequence of HLH itself. Further studies using ELISA that can distinguish between human and viral IL-10 will be necessary. A soluble hemoglobin scavenger receptor (sCD163) is also shed from the monocyte-macrophage membrane upon inflammatory stimuli and reflects anti-inflammatory processes [15]. Interestingly, our results for sCD163 indicate alternative activation of macrophages, in addition to classical activation, in primary EBV infection. HO-1 is the rate-limiting enzyme in the heme breakdown pathway, and has potent anti-inflammatory, anti-apoptotic, and anti-oxidative effects [19]. It has recently been reported that HO-1 is useful in the differential diagnosis of secondary HLH [20]. Indeed, our EBV-HLH patients exhibited higher levels of HO-1. Taken together, the profiles of anti-inflammatory mediators among EBV-HLH, EBV-IM, and FHL were largely similar to the profiles of pro-inflammatory cytokines.

In summary, our studies demonstrate significantly higher concentrations of both pro-inflammatory cytokines and anti-inflammatory mediators in EBV-HLH compared

with EBV-IM. These profiles may contribute to the disease pathogenesis of EBV-HLH by activating and inhibiting host immune responses.

Acknowledgments

We thank Ms Harumi Matsukawa, Ms. Shizu Kouraba and Ms. Miho Nishio for their excellent technical assistance. This work was supported by a grant from Hokkoku Gan Kikin fund, Kanazawa; a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan; and a grant from the Ministry of Health, Labour, and Welfare of Japan, Tokyo.

Conflict of interest

Nothing to declare.

References

1. Hislop AD, Taylor GS, Sauce D, et al. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. *Annu Rev Immunol* 2007;25:587-617.
2. Ishii E, Ohga S, Imashuku S, et al. Review of hemophagocytic lymphohistiocytosis (HLH) in children with focus on Japanese experiences. *Crit Rev Oncol Hematol* 2005;53(3):209-223.
3. Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. *Annu Rev Med* 2012;63:233-246.
4. Kasahara Y, Yachie A, Takei K, et al. Differential cellular targets of Epstein-Barr virus (EBV) infection between acute EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. *Blood* 2001;98(6):1882-1888.
5. Toga A, Wada T, Sakakibara Y, et al. Clinical significance of cloned expansion and CD5 down-regulation in Epstein-Barr Virus (EBV)-infected CD8+ T lymphocytes in EBV-associated hemophagocytic lymphohistiocytosis. *J Infect Dis* 2010;201(12):1923-1932.
6. Wada T, Kurokawa T, Toma T, et al. Immunophenotypic analysis of Epstein-Barr virus (EBV)-infected CD8(+) T cells in a patient with EBV-associated hemophagocytic lymphohistiocytosis. *Eur J Haematol* 2007;79(1):72-75.
7. Ito Y, Kawamura Y, Iwata S, et al. Demonstration of type II latency in T lymphocytes of Epstein-Barr Virus-associated hemophagocytic lymphohistiocytosis. *Pediatr Blood Cancer* 2012. in press.

8. Williams H, Macsween K, McAulay K, et al. Analysis of immune activation and clinical events in acute infectious mononucleosis. *J Infect Dis* 2004;190(1):63-71.
9. Wright-Browne V, Schnee AM, Jenkins MA, et al. Serum cytokine levels in infectious mononucleosis at diagnosis and convalescence. *Leuk Lymphoma* 1998;30(5-6):583-589.
10. Attarbaschi T, Willheim M, Ramharter M, et al. T cell cytokine profile during primary Epstein-Barr virus infection (infectious mononucleosis). *Eur Cytokine Netw* 2003;14(1):34-39.
11. Tang Y, Xu X, Song H, et al. Early diagnostic and prognostic significance of a specific Th1/Th2 cytokine pattern in children with haemophagocytic syndrome. *Br J Haematol* 2008;143(1):84-91.
12. My LT, Lien le B, Hsieh WC, et al. Comprehensive analyses and characterization of haemophagocytic lymphohistiocytosis in Vietnamese children. *Br J Haematol* 2010;148(2):301-310.
13. Xu XJ, Tang YM, Song H, et al. Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children. *J Pediatr* 2012;160(6):984-990 e981.
14. Shimizu M, Yokoyama T, Yamada K, et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. *Rheumatology (Oxford)* 2010;49(9):1645-1653.
15. Yamazaki H, Ohta K, Tsukiji H, et al. Corticosteroid enhances heme oxygenase-1 production by circulating monocytes by up-regulating hemoglobin scavenger

- receptor and amplifying the receptor-mediated uptake of hemoglobin-haptoglobin complex. *Biochem Biophys Res Commun* 2007;358(2):506-512.
16. Ibarra MF, Klein-Gitelman M, Morgan E, et al. Serum neopterin levels as a diagnostic marker of hemophagocytic lymphohistiocytosis syndrome. *Clin Vaccine Immunol* 2011;18(4):609-614.
 17. Imashuku S, Hibi S, Ohara T, et al. Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. *Histiocyte Society. Blood* 1999;93(6):1869-1874.
 18. Kanegane H, Wakiguchi H, Kanegane C, et al. Viral interleukin-10 in chronic active Epstein-Barr virus infection. *J Infect Dis* 1997;176(1):254-257.
 19. Ohta K, Yachie A. Development of vascular biology over the past 10 years: heme oxygenase-1 in cardiovascular homeostasis. *J Endovasc Ther* 2004;11 Suppl 2:II140-150.
 20. Miyazaki T, Kirino Y, Takeno M, et al. Serum HO-1 is useful to make differential diagnosis of secondary hemophagocytic syndrome from other similar hematological conditions. *Int J Hematol* 2010;91(2):229-237.

Figure Legends

Fig. 1. Cytokine profiles in patients with EBV-HLH, EBV-IM, and FHL.

Serum or plasma concentrations of interferon- γ , neopterin, interleukin (IL)-6, IL-18, tumor necrosis factor (TNF)- α , soluble TNF receptor type 1 (sTNF-RII) and type 2 (sTNF-RII), IL-10, soluble CD163 (sCD163) and heme oxygenase-1 (HO-1). Horizontal bars indicate the median values. Shaded areas represent the ranges of normal values. EBV, Epstein-Barr virus; HLH, hemophagocytic lymphohistiocytosis; IM, infectious mononucleosis; FLH, familial HLH; n.s., not significant. * $p < 0.05$; ** $p < 0.01$; *** $p \leq 0.001$.

